MENLO PARK, Calif.--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.

加利福尼亚州门洛帕克（BUSINESS WIRE）-Summit Therapeutics Inc.（纳斯达克股票代码：SMMT）（“Summit”，“we”或“公司”）今天宣布，Howard“Jack”West，医学博士已加入Summit Therapeutics担任肺癌临床开发副总裁。

“Dr. West brings a wealth of experience, and his knowledge in treating lung cancer patients is unrivaled,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of the Company. “To bring a key lung cancer expert the stature of Dr. West speaks volumes about Team Summit and our mission to make a significant, positive difference in the lives of patients facing this terrible disease.

该公司首席执行官兼总裁Maky Zanganeh博士说：“West博士带来了丰富的经验，他在治疗肺癌患者方面的知识无与伦比。“为了聘请一位重要的肺癌专家，West博士的地位讲述了有关团队峰会的内容，以及我们的使命，即在面临这种可怕疾病的患者的生活中做出重大积极的改变。

We are thrilled to welcome Jack to our team.”.

我们很高兴欢迎杰克来到我们的团队。”。

Dr. West joins Summit from City of Hope, one of the nation’s leading cancer treatment and research centers. At City of Hope, he was the Vice President of Network Strategy at AccessHope, an enterprise that provides remote expertise from cancer sub-specialists for patients around the US, as well as an Associate Professor and practicing medical oncologist.

West博士参加了希望之城峰会，希望之城是全国领先的癌症治疗和研究中心之一。在希望之城，他是AccessHope网络战略副总裁，该企业为美国各地的患者提供癌症亚专家的远程专业知识，以及副教授和执业医学肿瘤学家。

Dr. West brings over 25 years of experience as a practicing thoracic oncologist. Prior to joining City of Hope, Dr. West spent over 15 years at Providence Health & Services, including time as the Medical Director of the Thoracic Oncology Program. As a practicing physician, Dr. West has been a principal investigator in over 20 clinical trials in lung cancer.

West博士拥有超过25年的胸部肿瘤执业经验。在加入希望之城之前，West博士在Providence Health＆Services工作了15年以上，其中包括担任胸部肿瘤项目医疗主任的时间。作为一名执业医师，West博士一直是20多项肺癌临床试验的首席研究员。

Dr. West is also the Founder and former President of GRACE, the Global Resource for Advancing Cancer Education, and the President of Go West Health Care Consulting, providing in depth knowledge about current and emerging cancer treatments. He has been responsible for publishing treatment guidelines and medical provider point-of-care resource guides such as Medscape and UpToDate.

West博士还是全球推进癌症教育资源GRACE的创始人兼前总裁，也是Go West医疗保健咨询总裁，深入了解当前和新兴的癌症治疗方法。他一直负责发布治疗指南和医疗服务提供者护理点资源指南，例如Medscape和UpToDate。

Dr. West earned his medical degree from Harvard Medical School, was the Howard Hughes Medical Student Research Fellow at Massachusetts General Hospital, and did his medical oncology fellowship training at the University of Washington Fred Hutchinson Cancer Research Center..

West博士在哈佛医学院获得医学学位，是马萨诸塞州总医院霍华德·休斯医学生研究员，并在华盛顿大学弗雷德·哈钦森癌症研究中心接受了医学肿瘤学奖学金培训。。

“Bolstering our team with someone with the breadth and depth of experience and expertise such as Jack West is an honor for me and Team Summit,” added Dr. Allen S. Yang, Chief Medical Officer at Summit. “Dr. West is a respected thoracic oncology expert who has worked with nearly every treatment in lung cancer over the past 25 years – whether through providing patient care, leading clinical trials, or disseminating treatment guidance.

峰会首席医疗官Allen S.Yang博士补充说：“为我和团队峰会等拥有丰富和深入经验和专业知识的人支持我们的团队是我和团队峰会的荣幸。“West博士是一位受人尊敬的胸部肿瘤学专家，在过去的25年中，无论是通过提供患者护理，领导临床试验还是传播治疗指导，几乎所有的肺癌治疗都在工作。

His stature and expertise are valued resources as we continue to advance and develop our novel, potentially first-in-class bispecific antibody, ivonescimab*.”.

随着我们继续推进和开发我们的新型，潜在的一流双特异性抗体ivonescimab*，他的身材和专业知识是宝贵的资源。

“Throughout my career, in addition to caring for patients, I have focused on providing knowledge and access to the best possible care in the particularly challenging field of thoracic oncology,” noted Dr. West. “While treatment options have advanced greatly over the past 25 years, every lung cancer clinic illustrates the ongoing need for additional advances.

West博士指出：“在我的职业生涯中，除了照顾病人之外，我还专注于在特别具有挑战性的胸部肿瘤学领域提供知识和获得最佳护理。”。“虽然过去25年来治疗方案取得了很大进展，但每个肺癌诊所都说明了对进一步发展的持续需求。

The opportunity to work with an outstanding team at Summit, contributing to the development of ivonescimab, an investigational product with great potential, offers me a new path to improving the lives of patients.”.

有机会与峰会的杰出团队合作，为开发具有巨大潜力的研究产品ivonescimab做出贡献，为我改善患者生活提供了一条新途径“。

Summit Therapeutics’ Mission Statement

峰会治疗学的使命声明

To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, and successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs.

建立一个可行，持久的医疗保健组织，全面负责设计，开发，试验执行和注册，监管提交和批准，以及患者，医生，护理人员和社会友好药物治疗的成功商业化，旨在：改善生活质量，增加潜在的生命周期，并解决严重的医疗保健需求。

To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate..

为了根据卓越的科学发展和管理专业知识确定和控制有希望的候选产品，以快速，经济高效的方式开发我们的产品，并在适当的时候聘请商业化和/或开发合作伙伴。。

We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.

我们通过建立一个由世界级专业科学家和企业管理人员组成的团队来实现这一目标，他们将自己的经验和知识应用于这一使命。团队峰会的存在是为了构成，制定战略并执行药物治疗保健方面的前进道路，使峰会处于一个应得的顶级市场份额和领导地位。

Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders..

Team Summit负全部责任，促进所有相关利益相关者和高价值股东不断扩大知识，能力，能力和福祉。。

About Ivonescimab

Ivonescimab

Ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

Ivonescimab，在美国，加拿大，欧洲和日本（Summit的许可地区）被称为SMT112，在中国和澳大利亚被称为AK112，是一种新型的，潜在的一流的研究性双特异性抗体，结合了免疫疗法的效果通过阻断PD-1与将VEGF阻断成单个分子相关的抗血管生成作用。

Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Summit has begun its clinical development of ivonescimab in NSCLC, enrolling the first patient in its license territory in 2023, with multiple Phase III clinical trials intended to be initiated in 2023.

Ivonescimab由Akeso Inc.（HKEX代码：9926.HK）发现，目前正在进行多项III期临床试验。Summit已开始在NSCLC中开展ivonescimab的临床开发，于2023年在其许可区域招募第一名患者，并计划于2023年启动多项III期临床试验。

Over 825 patients have been treated with ivonescimab in clinical studies in China and Australia, with enrollment beginning recently in the United States..

在中国和澳大利亚的临床研究中，已有825例患者接受了ivonescimab治疗，最近在美国开始招募。。

About Summit Therapeutics

关于Summit Therapeutics

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK.

峰会成立于2003年，我们的股票在纳斯达克全球市场（符号'SMMT'）上市。我们总部设在加利福尼亚州门洛帕克，我们在英国牛津设有额外的办事处。

For more information, please visit https://www.smmttx.com and follow us on X (formerly Twitter) @summitplc.

欲了解更多信息，请访问https://www.smmttx.com然后跟随我们X（以前的Twitter）@summitplc。

Summit Forward-looking Statements

峰会前瞻性声明

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials, potential acquisitions and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中有关本公司未来期望，计划和前景的任何声明，包括但不限于有关本公司产品候选人的临床和临床前发展，与Akeso Inc.合作的进入和行动相关的声明，治疗公司产品候选人的潜力，公司候选产品的潜在商业化，临床试验数据的启动，完成和可用时间，上市批准申请的潜在提交，COVID-19大流行对公司运营和临床试验的影响，潜在收购和其他包含“预期”一词的陈述，相信，“继续”，“可以”，“估计”，“期望”，“打算”，“可能”，“计划”，“潜力”，“预测”，“项目”，“应该”，“目标”，“将会”和类似的表达，构成1995年“私人证券诉讼改革法”含义内的前瞻性陈述。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for SMT112, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial .

由于各种重要因素，实际结果可能与此类前瞻性声明所表明的结果大不相同，包括我们对与SMT112开发和商业化活动有关的基础数据的评估结果，与监管机构讨论的结果，包括食品和药物管理局，未来临床试验开始时固有的不确定性，正在进行的和未来的临床试验数据的可用性和时间，这些试验的结果及其成功，以及全球公共卫生危机，包括冠状病毒COVID-19爆发，可能会影响我们临床试验和手术的时间和状态，无论是临床试验的初步结果。

* Ivonescimab is an investigational therapy that is not approved by any regulatory agency.

*Ivonescimab是一种未经任何监管机构批准的研究性治疗。